DD Stock Forecast & Price Target

DuPont de Nemours is favorably positioned because Healthcare and Water Technologies delivered mid-single-digit organic sales growth in Q2 and are expected to keep compounding, while Diversified Industrials still posted in-line 3% organic growth despite B&C weakness. Its earnings power is supported by solid free cash flow, over 100% FCF conversion in Q2, margins near 24.5% for FY26, and management’s plan for more than $500M of buybacks in 2026 alongside further debt reduction. With continued organic improvement, pricing discipline, and bolt-on M&A optionality from roughly $1B available for acquisitions, the company appears set for strong EPS growth into FY27 and beyond.

DuPont de Nemours is facing a negative setup because its downside case already assumes only $7.20 of 2026E EPS and $2.17 of 2026E EBITDA, which still relies on an 18x or 21x multiple despite significant uncertainty. The core issues are delayed synergy realization, integration friction, and a failure to optimize the spin strategy, all of which can pressure margins and slow earnings conversion. Weakness in electronics and construction, plus a slower recovery in China and North America, further clouds demand and raises the risk that the company’s healthcare and water strengths are not enough to offset broader cyclical softness.